Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with ...
3d
The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.
With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.
Long-term data from the pivotal phase 3 ELARA trial showed durable efficacy with tisagenlecleucel in high-risk follicular ...
When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of ...
These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...
GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 ...
Presentation: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback